Novartis Biologics Center
Basel, Switzerland
Immunogenicity against biotherapeutic drugs, an immune response, which could result in the formation of anti-drug antibodies and drug-specific T cells, is a common effect, which can have an impact on the efficacy of the biotherapeutic and the safety of the patient. Our work is focused on understanding the immune mechanisms that contribute to the development of immunogenicity and downstream effects. We are applying state of the art immunology, proteomics and molecular biology technologies on human samples derived from healthy volunteers and patients from clinical trials. We are working in a highly collaborative environment with many groups at Novartis Institutes for Biomedical Research and Global Drug Development, connecting also with academic university hospitals. A human translational sciences approach will provide new insights for the development of transformative medicines with a better safety and efficacy profile.